JCAR 018

Drug Profile

JCAR 018

Alternative Names: Anti-CD22 chimeric antigen receptor T cell therapy - National Cancer Institute/Opus Bio; Anti-CD22 human single chain variable fragment CAR T cell therapy - National Cancer Institute/Opus Bio; Anti-CD22-CAR T cell therapy - National Cancer Institute/Opus Bio; anti-CD22-CAR transduced T cells - National Cancer Institute/Opus Bio; Anti-CD22-human scFv CAR T cell product - National Cancer Institute/Opus Bio; Anti-CD22-human scFv CAR T cell therapy - National Cancer Institute/Opus Bio

Latest Information Update: 14 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator National Cancer Institute (USA); Opus Bio
  • Developer National Cancer Institute (USA)
  • Class Cancer vaccines; CAR-T cell therapies; Gene therapies; T lymphocyte cell therapies
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Acute lymphoblastic leukaemia; Non-Hodgkin's lymphoma

Most Recent Events

  • 02 Nov 2017 National Cancer Institute suspends patient enrolment in a phase I trial in Acute lymphoblastic leukaemia & Non-Hodgkin's lymphoma (Second-line therapy or greater, In infants, In children, In adolescents, In adults) in USA (IV) (NCT02315612)
  • 03 Dec 2016 Interim efficacy and adverse events data from a phase I trial in Acute lymphoblastic leukaemia presented at the 58th American Society of Hematology Annual Meeting and Exposition (ASH-2016)
  • 06 Dec 2015 Interim efficacy and adverse events data from a phase I trial in Acute lymphoblastic leukaemia released by Juno
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top